Hollencrest Capital Management’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$88.3K Hold
1,841
0.01% 471
2026
Q1
$67.7K Sell
1,841
-1,047
-36% -$49.6K ﹤0.01% 499
2025
Q4
$147K Sell
2,888
-139
-5% -$7.11K 0.01% 392
2025
Q3
$168K Sell
3,027
-1,278
-30% -$74.8K 0.01% 345
2025
Q2
$297K Hold
4,305
0.01% 244
2025
Q1
$299K Sell
4,305
-251
-6% -$20.7K 0.01% 237
2024
Q4
$392K Sell
4,556
-325
-7% -$35.1K 0.02% 227
2024
Q3
$581K Sell
4,881
-996
-17% -$133K 0.02% 198
2024
Q2
$839K Sell
5,877
-1,132
-16% -$150K 0.04% 156
2024
Q1
$900K Buy
7,009
+989
+16% +$118K 0.04% 149
2023
Q4
$623K Buy
6,020
+56
+0.9% +$5.54K 0.06% 167
2023
Q3
$542K Buy
5,964
+1,130
+23% +$99.5K 0.06% 164
2023
Q2
$391K Buy
4,834
+750
+18% +$61.3K 0.04% 205
2023
Q1
$325K Sell
4,084
-24
-0.6% -$1.7K 0.03% 219
2022
Q4
$278K Buy
+4,108
New +$241K 0.03% 219

Other funds holding NVO

Hollencrest Capital Management's NVO Position: Q2 2026 in Review

Hollencrest Capital Management held its Novo Nordisk (NVO) position steady in Q2 2026 at 1,841 shares worth $88.3K. The position accounts for 0.01% of the portfolio, ranked #471.

Hollencrest Capital Management first reported a position in NVO in Q4 2022 and has held it in 15 quarters since. The position peaked at $900K in Q1 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Hollencrest Capital Management held 1,841 shares of Novo Nordisk worth $88.3K as of Q2 2026.
  • Hollencrest Capital Management left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.01% of Hollencrest Capital Management's portfolio in Q2 2026, its #471 holding.
  • Hollencrest Capital Management first reported a position in Novo Nordisk in Q4 2022 and has held it in 15 quarters since.
  • Hollencrest Capital Management's Novo Nordisk position peaked at $900K in Q1 2024.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hollencrest Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.